Iambic Therapeutics (IAM) stock

Novel medicines , market cap $695M

Novel medicines using molecular platform

Market cap $695M

$14.41

+1.05%

After-hours $14.17 -1.66%

As of 7:29 PM ET after-hours, delayed 15+ min · Live for Pro members

Quality Score

New listing

Checks firing

1of 14

Transition

From its high

-42.4%

No 200-day yet

IAM's Quality Score rose 1 point on Fri, Oct 23, to 3. Closed near the day's high.

Trading since Oct 15, 2026. 8 trading days so far, so 11 of the 14 chart checks wait for more history.

Follow IAM's trial news. Pro members can get an alert when Iambic Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IAM files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on IAM

Key facts on IAM
Latest filing	8-K, Oct 16 Changed its bylaws or fiscal year

IAM in the news

Tue Oct 20Form 4 Iambic Therapeutics: Michael Secora (CFO & Chief Corp Dev Ofcr) For: 16 October By Investing.com investing.com south africa and 3 more · yesterday 8:16 PM ET IAM closed −2.0% that day.

IAM catalysts

Coming up

1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for IAM

Its trials

A trial underway: IAM1363 in HER2 CancersPhase 1 · Recruiting · 383 people · main data estimated Dec 2027 · NCT06253871

For Pro members: 1 filing.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Evan Lockwood Rachlin bought 718,750 shares on Oct 16.

From Form 4: open-market buys and sales only.

Get an alert when Thomas Miller buys or sells

For Pro members: every trade, and Thomas Miller’s 2 filings and quotes.

Get an alert when IAM files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Why IAM scores 3

New listingTransition, 1 of 14 chart checks firingWhat the Quality Score means

+1Chart checks 1 of 14 firing right now, one point each
+2Insider trades Evan Lockwood Rachlin (Director) bought $11.5M on Oct 16

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on IAM and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 7:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when IAM's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on IAM and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

IAM has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on IAM, and all 14 on every stock.Get in free →

The deep dive on IAM

What it does and how it makes money1 findingFor Pro members1 finding on what IAM does and how it makes money, for Pro members
Who holds and trades it1 findingDirector Evan Lockwood Rachlin bought $11.5M of shares on the open market on Oct 16, 2026, the only insider trade in 90 days.Form 4, filed Oct 19, 2026

1 more finding on IAM, each with its source, for Pro membersGet in free →

How IAM ranks in Biotech

IAM is a new listing, ranked from its 22nd trading day.

How IAM ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	RIGLRigel Pharmaceuticals	9/14	19
3	MEDPMedpace	7/14	19
	HRMYHarmony Biosciences		Open for its score
	HURATuHURA Biosciences		Open for its score
	IBRXImmunityBio		Open for its score
	ICLRIcon		Open for its score
New	IAMIambic Therapeutics	1/14	3

IAM share count over time

Offerings, shelves, and splits of IAM, from its filings
From its filings	Filed
Raised $150M in a sale of shares, about 22% of its market value	Oct 15, 2026
Registered shares for sale (S-1)	Sep 21, 2026

Who is trading IAM

IAM insider trades

One insider bought $11.5M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyEvan Lockwood Rachlin$11.5MDirectorat $16.00 on Oct 16, filed Oct 19

BuyEvan Lockwood RachlinDirector$11.5Mat $16.00 on Oct 16, filed Oct 19

IAM's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Thomas F. MillerChief Executive Officer
Michael SecoraCFO & Chief Corp Dev Ofcr
Frederick R. ManbyChief Technology Officer
Neil JosephsonChief Medical Officer
Peter A. OlsonChief Scientific Officer
Evan Lockwood RachlinDirector · 1 trade
R. Jacob VogelsteinDirector
William H. RastetterDirector

See insider trades by person

About Iambic Therapeutics

Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.

iambic.ai

Listed on Nasdaq on Oct 15, 2026, and is 9.9% below its $16 offer price now. Its IPO filing and first days

IAM's score card

Iambic Therapeutics (IAM): Quality Score 3, New listing, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn IAM's score around: 1 thing
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 19Evan Lockwood Rachlin bought IAM$11.5M at $16.00, filed Oct 19

Alerts are optional.

See IAM's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: IAM's Quality Score is 3 (New listing). Insiders bought $11.5M in the last 6 months (Form 4).

Is IAM a good stock to buy? What its Quality Score says

IAM scores 3 today, which Breakaway calls Below Average. It has 1 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IAM's Quality Score?

IAM scores 3 today, which Breakaway calls Below Average (0 to 5). The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IAM's 3.

Are insiders buying IAM?

One insider bought $11.5M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is Evan Lockwood Rachlin, Director, who bought $11.5M on Oct 16.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.